Explainer: What Does New Data Say About Gilead’s Experimental Coronavirus Drug?
May 1, 2020
(Reuters) – New clinical data on Gilead Sciences Inc’s experimental antiviral drug remdesivir has raised hopes it might be an effective treatment for the novel coronavirus that has infected more than 3 million people and killed over 225,000 worldwide. On Wednesday, partial data from three different trials of the drug were released, creating both excitement and confusion.Much analysis and more studies are needed to understand which COVID-19 patients are most likely to benefit from the drug if it is deemed effective, under what circumstance it should be given, and whether it has any impact on the death rate. The following is what we do know about the latest three studies.